Programmed death ligand-1 (PD-L1) is an important target of tumor immunotherapy in clinical trials and has a significant therapeutic effect on liver hepatocellular carcinoma (LIHC) and non-small-cell lung cancer (NSCLC) [8, 9]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.